Hashad Yehia 4

What Happened
Hashad Yehia, EVP of R&D and Chief Medical Officer at Bausch & Lomb (BLCO), was reported as acquiring 29,406 shares on 2026-02-18 as an award (Form 4 code A). The filing shows an acquisition price of $0 because these are performance stock units (PSUs) that satisfied their performance criteria; the earned PSUs are scheduled to vest on March 1, 2026, subject to continued employment.

Key Details

• Transaction date: 2026-02-18 (reported on Form 4 filed 2026-02-20).
• Transaction type/code: Award/Grant (A).
• Shares: 29,406 common shares recorded as acquired at $0.00 (reflects an awarded PSU conversion, not a cash purchase).
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: These represent PSUs originally granted March 1, 2023 under the Bausch + Lomb 2022 Omnibus Incentive Plan; performance conditions were met as of Feb 18, 2026 and the earned units will vest Mar 1, 2026, subject to continued employment.
• Filing timeliness: No late-filing flag indicated.

Context
PSUs are performance-based equity awards that convert to shares only after performance metrics and service conditions are met; the $0 acquisition price on the Form 4 reflects that this was an awarded grant, not a market purchase. Such compensation disclosures are common and reflect company pay practices; they are informational rather than direct signals of insider buying or selling intent.